$34.60 0.99 (2.95%)
19:59 EDT PFE Stock Quote Delayed 20 Minutes
Previous Close $34.60
Market Cap 202.40B
PE Ratio 9.61
Volume (Avg. Vol.) 24.22M
Day's Range 33.44 - 34.80
52-Week Range 27.88 - 44.56
Dividend & Yield 1.36 (3.93%)
PFE Stock Predictions, Articles, and Pfizer News
- From InvestorPlace
- From the Web
Not all blue-chip stocks are good to hold forever. These companies are struggling to cut costs and could fall further. Sell them now.
By David Moadel
Monday's big stock charts feature names that may have downside protection in the form of trendline support.
Stocks popped Friday as investors sought coronavirus clarity from the White House and speculated the Fed could cut rates to zero.
Pfizer has seriously underperformed in recent years. Down 10.8% year to date, Pfizer stock remains an underdog.
Pfizer stock is gearing up for a strong 2020 as the company spins out is generics drug business, completing a merger with Mylan.
Pfizer stock had a good day on Wednesday, but remains a bad bet for investors. The Mylan-Upjohn spinoff later this year will sap its value.
Uber gets a new buy rating, while BorgWarner buys Delphi for about $3.3 billion. Here's what happened in the stock market today.
Apple, General Electric, Pfizer and MMM were our top stock trades for Wednesday. That said, here's a look at the charts for the stocks.
Pfizer (PFE) earnings for the pharmaceutical company's fourth quarter of 2019 have PFE stock falling hard Tuesday on an EPS miss.
Pfizer stock offers good value to patient investors. Pfizer's new spinoffs will provide a higher total return to the owners of Pfizer stock.
Tuesday's big stock charts focus on 3 value plays that are looking to continue recent breakouts.
The December jobs report was't as strong as economists expected and that triggered some modest selling on Wall Street to close the week.
Pfizer stock has no momentum right now. Earnings and revenue are in decline and the charts are struggling. I would avoid for now.
FDA approval of Vascepa in use for cardiovascular events just widened Amarin’s revenue potential. Amarin stock should have a banner 2020.
By Thomas Niel
Wall Street has discounted Pfizer's divestiture plans. But spinning off off-patent drugs could improve the valuation of PFE stock.
These 10 stocks had an ugly 2019 — but the outlook for 2020 looks much brighter.
With another year in the history books, investors are turning to popular year-end strategies. With that said, one of my personal favorites is the Dogs of the Dow.
From Seeking Alpha
From Talk Markets
Navellier RatingsPowered by Portfolio Grader